Azorsa and colleagues recently identified CHK1 as a therapeutic target for sensitizing pancreatic cancer cells to gemcitabine therapy using a synthetic lethal RNAi screening approach [10]. This evidence concerns the gene CHEK1 and pancreatic neoplasm.